A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

R. Scott Turner; Ronald G. Thomas; Suzanne Craft; Christopher H. van Dyck; Jacobo Mintzer; Brigid A. Reynolds; James B. Brewer; Robert A. Rissman; Rema Raman; Paul S. Aisen; For the Alzheimer's Disease Cooperative Study

doi:10.1212/WNL.0000000000002035

Full PDF

Citation

Permissions

Make Comment

See Comments

Downloads

17764

Article Figures & Data

Figures

Tables
Additional Files

Download figure

Open in new tab

Download powerpoint

Figure 1 Flow diagram and disposition of the treatment groups
MMSE = Mini-Mental State Examination.
Download figure

Open in new tab

Download powerpoint

Figure 2 Effects of resveratrol on Aβ levels
Resveratrol altered levels of CSF Aβ40 (A) and plasma Aβ40 (B) (ng/mL, mean ± SE). Similar but nonsignificant trends were found for CSF Aβ42 (C) and plasma Aβ42 (D) (ng/mL, mean ± SE). Note difference in scales. Sample sizes are indicated.
Download figure

Open in new tab

Download powerpoint

Figure 3 Effects of resveratrol on brain volume
Resveratrol increased brain volume loss (A, C) (mL, mean ± SE) with a corresponding increase in ventricular volume (B, D) (mL, mean ± SE). Sample sizes are indicated.

Additional Files

Figures
Tables

Data Supplement

Two tables, two figures, and one appendix; three PDF files and one Microsoft Word file.

Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2015 American Academy of Neurology.

Files in this Data Supplement:

Tables e-1 to e-2 - PDF file
Figure e-1 - PDF file
Figure e-2 - PDF file
Appendix e-1 - Microsoft Word file
Coinvestigators

Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2015 American Academy of Neurology.

Files in this Data Supplement:

Coinvestigators - Microsoft Word file

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

Stay timely. Submit only on articles published within 6 months of issue date.
Do not be redundant. Read any comments already posted on the article prior to submission.
200 words maximum.
5 references maximum. Reference 1 must be the article on which you are commenting.
5 authors maximum. Exception: replies can include all original authors of the article.
Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

Title *

Author Information

NOTE: The first author must also be the corresponding author of the comment.

Authors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Publishing Agreement

I, the first and corresponding author, verify that I have read the contents of the PUBLISHING AGREEMENT form. *

I, the first and corresponding author, verify my disclosures and those of my co-authors are up to date at http://submit.neurology.org. *

Select only one of the three options below: *

I am an Author of this Work, and the Work was prepared on my own time - not as part of my duties as an employee.

I prepared (or cooperated in the preparation of) the Work as part of my duties as an employee, and the Work is, therefore, a "work made for hire", as defined by the United States Copyright Act of 1976, as amended.

I prepared (or participated in the preparation of) the Work as part of my official duties as an officer or employee of the United States Government.

NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Main menu

User menu

Search

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

Citation Manager Formats